Pet Cancer Therapeutics Market

Global Pet Cancer Therapeutics Market Size, Share and Trends Analysis Report, By Therapy (Chemotherapy, Radiation therapy, Immunotherapy, and Others), By Animal (Dogs, Cats, and Others), By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, and Others), Forecast (2021-2027)

Published: Jan 2022 | Report Code: OMR2025550 | Category : Pharmaceuticals | Delivery Format: /

The global pet cancer therapeutics market is anticipated to grow at a significant CAGR during the -forecast period (2021-2027). The major factors that are influencing the growth of the market include the growing prevalence of several types of cancers in cats and dogs, as well as an increase in animal health awareness. The most common cancers in cats include leukaemia and lymphoma. Cancer is one of the major causes of mortality in pets, mainly in dogs that are older than 10 years. The success rate of various treatments in preventing and curing neoplasia, and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early screening, diagnosis, and treatment methods. 

According to FETCH a Cure, a non-profit organization, an estimated 6 million dogs were diagnosed with cancer in 2019 across the globe. This indicates that there is an increasing need for cancer treatment in dogs, which is likely to accelerate the growth of the market during the forecast period. Moreover, the other factors that are expected to boost the market include an increase in the adoption of dogs across the globe and an increase in R&D initiatives regarding pet cancer management by the players, which are expected to propel the market growth during the forecast period. For instance, in April 2019, Elanco signed a development and commercialization agreement with VetDC for Tanovea-CA1, and, the first US Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Boehringer Ingelheim GmbH (Merial), Zoetis Inc., and Elanco Animal Health Inc., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Pet Cancer Therapeutics Market Report by Segment

By Therapy 

Chemotherapy

Radiation therapy

Immunotherapy

Others

By Animal 

Dogs

Cats

Others

By Application 

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

Global Pet Cancer Therapeutics Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World